{"id":"https://openalex.org/W1978345770","doi":"https://doi.org/10.4088/jcp.v62n0412","title":"An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder","display_name":"An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder","publication_year":2001,"publication_date":"2001-04-15","ids":{"openalex":"https://openalex.org/W1978345770","doi":"https://doi.org/10.4088/jcp.v62n0412","mag":"1978345770","pmid":"https://pubmed.ncbi.nlm.nih.gov/11379844"},"language":"en","primary_location":{"id":"doi:10.4088/jcp.v62n0412","doi":"https://doi.org/10.4088/jcp.v62n0412","is_oa":false,"landing_page_url":"https://doi.org/10.4088/jcp.v62n0412","pdf_url":null,"source":{"id":"https://openalex.org/S17992710","display_name":"The Journal of Clinical Psychiatry","issn_l":"0160-6689","issn":["0160-6689","1534-8628","1555-2101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4322614534","host_organization_name":"Physicians Postgraduate Press, Inc.","host_organization_lineage":["https://openalex.org/P4322614534"],"host_organization_lineage_names":["Physicians Postgraduate Press, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031288381","display_name":"Cathy L. Budman","orcid":"https://orcid.org/0000-0001-5747-9794","observed_orcids":["https://orcid.org/0000-0001-5747-9794"]},"institutions":[{"id":"https://openalex.org/I2800496781","display_name":"North Shore University Hospital","ror":"https://ror.org/05m8d2x46","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339","https://openalex.org/I2800496781"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cathy L. Budman","raw_affiliation_strings":["Department of Psychiatry, New York University School of Medicine, North Shore University Hospital, Manhasset 11030, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, New York University School of Medicine, North Shore University Hospital, Manhasset 11030, USA","institution_ids":["https://openalex.org/I2800496781","https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056197654","display_name":"ALEX I. GAYER","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Gayer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012284725","display_name":"MARTIN L. LESSER","orcid":"https://orcid.org/0000-0002-0318-5739","observed_orcids":["https://orcid.org/0000-0002-0318-5739"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Lesser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102990090","display_name":"Qiuhu Shi","orcid":"https://orcid.org/0000-0003-3200-8309","observed_orcids":["https://orcid.org/0000-0003-3200-8309"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qiuhu Shi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5109224929","display_name":"RUTH DOWLING BRUUN","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ruth D. Bruun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":9.7826,"has_fulltext":false,"cited_by_count":111,"citation_normalized_percentile":{"value":0.97906829,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"62","issue":"4","first_page":"290","last_page":"294"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11123","display_name":"Obsessive-Compulsive Spectrum Disorders","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11123","display_name":"Obsessive-Compulsive Spectrum Disorders","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12684","display_name":"Stuttering Research and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tourette-syndrome","display_name":"Tourette syndrome","score":0.9850000143051147},{"id":"https://openalex.org/keywords/tics","display_name":"tics","score":0.7820000052452087},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.9150000214576721},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.5419999957084656},{"id":"https://openalex.org/keywords/tic-severity","display_name":"tic severity","score":0.7039999961853027},{"id":"https://openalex.org/keywords/yale-global-tic-severity-scale","display_name":"Yale Global Tic Severity Scale","score":0.8920000195503235},{"id":"https://openalex.org/keywords/sedation","display_name":"sedation","score":0.7139999866485596},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.8059999942779541},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5680000185966492},{"id":"https://openalex.org/keywords/obsessive-compulsive-symptoms","display_name":"obsessive-compulsive symptoms","score":0.6779999732971191},{"id":"https://openalex.org/keywords/comorbid-adhd","display_name":"ADHD comorbidity","score":0.8349999785423279},{"id":"https://openalex.org/keywords/flexible-dosing","display_name":"flexible dosing","score":0.5440000295639038}],"concepts":[{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.9071667194366455},{"id":"https://openalex.org/C2777200579","wikidata":"https://www.wikidata.org/wiki/Q738538","display_name":"Tics","level":2,"score":0.5819268822669983},{"id":"https://openalex.org/C2781353949","wikidata":"https://www.wikidata.org/wiki/Q3271533","display_name":"Dopamine antagonist","level":4,"score":0.5507333874702454},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5195308327674866},{"id":"https://openalex.org/C2776153860","wikidata":"https://www.wikidata.org/wiki/Q394129","display_name":"Psychomotor agitation","level":2,"score":0.4825007915496826},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4657006859779358},{"id":"https://openalex.org/C2777683783","wikidata":"https://www.wikidata.org/wiki/Q221174","display_name":"Topiramate","level":3,"score":0.45011743903160095},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.447493314743042},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4450315535068512},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.42526301741600037},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37272346019744873},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.33529388904571533},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.3119852542877197},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.28216296434402466},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.2037208378314972},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.1540963351726532},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.12616783380508423}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D001289","descriptor_name":"Attention Deficit Disorder with Hyperactivity","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005879","descriptor_name":"Tourette Syndrome","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D005879","descriptor_name":"Tourette Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005879","descriptor_name":"Tourette Syndrome","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.4088/jcp.v62n0412","doi":"https://doi.org/10.4088/jcp.v62n0412","is_oa":false,"landing_page_url":"https://doi.org/10.4088/jcp.v62n0412","pdf_url":null,"source":{"id":"https://openalex.org/S17992710","display_name":"The Journal of Clinical Psychiatry","issn_l":"0160-6689","issn":["0160-6689","1534-8628","1555-2101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4322614534","host_organization_name":"Physicians Postgraduate Press, Inc.","host_organization_lineage":["https://openalex.org/P4322614534"],"host_organization_lineage_names":["Physicians Postgraduate Press, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Psychiatry","raw_type":"journal-article"},{"id":"pmid:11379844","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11379844","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2075216349","https://openalex.org/W2084904435","https://openalex.org/W30482998","https://openalex.org/W38920976","https://openalex.org/W2084272802","https://openalex.org/W2087320487","https://openalex.org/W2913519130","https://openalex.org/W7217446641","https://openalex.org/W37122809","https://openalex.org/W1991725979"],"abstract_inverted_index":{"BACKGROUND:":[0],"An":[1],"open-label":[2,242],"trial":[3],"was":[4,98],"performed":[5],"to":[6,39,93,152,232,254],"explore":[7],"efficacy":[8],"and":[9,23,25,81,110,119,129,139,178,204,263],"safety":[10],"of":[11,30,145,167,260],"olanzapine,":[12],"an":[13,48],"atypical":[14],"neuroleptic":[15,256],"with":[16,42,78],"diverse":[17],"receptor":[18],"activity":[19],"including":[20],"both":[21],"dopamine-2":[22],"serotonin-2A":[24],"-2C":[26],"antagonism,":[27],"for":[28,53,133,258],"treatment":[29,259],"Tourette's":[31,43,264],"disorder.":[32,265],"METHOD:":[33],"Ten":[34],"adult":[35],"patients":[36,57,73,83,147,157,220],"aged":[37],"20":[38,176,233],"44":[40],"years":[41],"disorder":[44],"were":[45,61,68,113,135,195,208,216],"treated":[46],"using":[47],"open-label,":[49],"flexible":[50],"dosing":[51],"schedule":[52],"8":[54,156],"weeks.":[55],"Three":[56,66],"who":[58,158],"continued":[59],"olanzapine":[60,150,226,246],"reevaluated":[62],"after":[63],"6":[64,179,222],"months.":[65],"subjects":[67],"psychotropic":[69],"medication":[70],"naive,":[71],"5":[72],"experienced":[74],"intolerable":[75],"side":[76,212],"effects":[77,112],"conventional":[79,94,255],"neuroleptics,":[80],"2":[82],"had":[84],"remote":[85],"(>":[86],"or":[87,174,185],"=":[88,175,186,237],"10":[89,146,187],"years)":[90],"successful":[91],"response":[92],"neuroleptics.":[95],"Tic":[96,104,214],"severity":[97,170],"rated":[99],"by":[100,123,172,183],"the":[101,124,160,209],"Yale":[102],"Global":[103],"Severity":[105],"Scale;":[106],"weight,":[107],"vital":[108],"signs,":[109],"adverse":[111],"assessed":[114,122],"weekly.":[115],"Electrocardiogram,":[116],"laboratory":[117],"studies,":[118],"comorbid":[120,193],"symptoms,":[121],"Yale-Brown":[125],"Obsessive":[126],"Compulsive":[127],"Scale":[128],"ADHD":[130],"Behavior":[131],"Checklist":[132],"Adults,":[134],"measured":[136],"at":[137,140],"baseline":[138],"week":[141],"8.":[142],"RESULTS:":[143],"Two":[144],"prematurely":[148],"discontinued":[149],"owing":[151],"excessive":[153],"sedation.":[154],"Of":[155],"completed":[159],"8-week":[161],"trial,":[162],"4":[163],"(50%)":[164],"demonstrated":[165,181],"reduction":[166],"global":[168],"tic":[169],"scores":[171],">":[173,184],"points,":[177],"(75%)":[180],"reductions":[182],"points.":[188],"No":[189],"significant":[190],"changes":[191],"in":[192,218],"symptoms":[194],"demonstrated.":[196],"Sedation,":[197],"weight":[198],"gain,":[199],"increased":[200],"appetite,":[201],"dry":[202],"mouth,":[203],"transient":[205],"asymptomatic":[206],"hypoglycemia":[207],"most":[210],"common":[211],"effects.":[213],"improvements":[215],"maintained":[217],"3":[219],"reassessed":[221],"months":[223],"later.":[224],"Final":[225],"dosages":[227],"ranged":[228],"from":[229],"2.5":[230],"mg":[231,234],"daily":[235],"(mean":[236],"10.9":[238],"mg/day).":[239],"CONCLUSION:":[240],"This":[241],"study":[243],"suggests":[244],"that":[245],"should":[247],"be":[248],"explored":[249],"as":[250],"a":[251],"potential":[252],"alternative":[253],"medications":[257],"motor":[261],"tics":[262]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}